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ABSTRACT
Pharmacokinetics, Tissue Distribution, Synergistic Activity, and Antitumor Activity of Two
Isomeric Flavones
by
Crystal Whitted
Flavonoids are polyphenolic secondary metabolites found in plants that have bioactive properties
including antiviral, antioxidant, and anticancer. Two isomeric flavones were extracted from
Gnaphalium elegans and Achyrocline bogotensis, plants used by the people from the Andean
region of South America as remedies for cancer. 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4Hchromen-4-one (5, 7–dihydroxy- 3, 6, 8 trimethoxy flavone/ flavone A) and 3,5-dihydroxy-6,7,8trimethoxy-2-phenyl-4H-chromen-4-one (3, 5–dihydroxy-6, 7, 8–trimethoxy flavone/ flavone B)
have shown antineoplastic activity against colon cancer cell lines dependent upon their
differentiation status. Pharmacokinetic studies reported herein were used to determine dosing for
antitumor assays, as well as determine target tissue concentration. These included the
development of methods to extract the flavones from plasma or colon tissue and reverse phase
high performance liquid chromatography methods for quantification. Quantification methods
were linear (r2 e 0.99) with plasma calibration curves ranging from 250 - 2,500 ng/mL and 2,500
- 100,000 ng/mL for both flavones and colon calibration curves ranging from 250 – 100,000 ng/g
(flavone A) and 1,000-25,000 ng/g (flavone B). Intravenous administration of a 20 mg/kg dose in
rats yielded half-lives of 83.68 ± 56.61 and 107.45 ± 53.31 minutes with clearance values of
12.99 ± 13.78 and 80.79 ± 35.06 mL/min/kg for flavones A and B, respectively. Analysis of
colon tissue yielded concentrations of 1639 ± 601 ng/g (flavone A) and 5975 ± 2480 ng/g
(flavone B), suggesting both may be good candidate for individual or adjunct therapy for colon
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cancer due to distribution to the target tissue. Preliminary studies in colon cancer cells CaCo 2
and HCT 116 using either flavone in combination with 5-fluorouracil (5-FU) suggested
synergistic activity of these compounds. The combination treatment increased induction of
apoptosis by enhancing the DNA damaging mechanism of 5-FU. In vivo, preliminary xenograft
experiments using HCT 116 cells showed smaller tumors in mice dosed with flavone B as
compared to the 5-FU or combination treatment. Further experiments are warranted to confirm
these observations.
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CHAPTER 1
INTRODUCTION
Flavonoids are polyphenolic secondary metabolites found in plants that have a common
phenylbenzopyrone structure (C6-C3-C6) (Figure 1). Over 5,000 flavonoids have been
discovered (Cai et al. 2003). These are divided into several subgroups depending on the presence
of double bonded oxygen, a hydroxyl group, a double bond in the C ring, or the carbon of the C
ring to which the B ring attaches (Figure 2) (Liu et al. 2010; Middleton et al. 2000).
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(Xiao et al. 2014). Another subgroup, flavonols are associated with a reduced risk of esophageal
cancer in current smokers (Vermeulen et al. 2013) and inversely associated with the risk of
bladder cancer (Zamora-Ros et al. 2014). Individual flavonoids such as eupatorin, apigenin,
naringen, aromadendrin, fisetin, nobiletin, and quercerin display antineoplastic properties in vitro
(Chiang et al. 2006; Choudhury et al. 2013; Doleckova et al. 2012; Khan et al. 2008; Surichan et
al. 2012; Wesolowska et al. 2007; Wu et al. 2005), while other flavonoids such as tectochrysin,
anthocyanin, kaempferol, and quercertin for example, display antitumor properties in vivo (Ha et
al. 2015; Park et al. 2015; Song et al. 2015; Yang et al. 2015).
Our laboratory investigates flavonoids from plants belonging to the family Compositae
(Asteraceae) including the genera Gnaphalium and Achyrocline. These are annual or perennial
herbs with worldwide distribution, and some are used for traditional folk medicine (Zheng et al.
2013). In the Andean region of South America, Gnaphalium elegans and Achyrocline
bogotensis are used to make hot beverages commonly recommended as a remedy for cancer.
Investigation into the compounds that are possibly responsible for the anticancer activity of these
plants has yielded a pair of isomeric flavones, 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4Hchromen-4-one (5, 7–dihydroxy- 3, 6, 8 trimethoxy flavone/ flavone A) and 3,5-dihydroxy-6,7,8trimethoxy-2-phenyl-4H-chromen-4-one (3, 5–dihydroxy-6, 7, 8–trimethoxy flavone/ flavone B)
(Figure 3) (Torrenegra et al. 1980; Torrenegra et al. 1982). In vitro, flavone A and flavone B
have differential antineoplastic activity against colon, pancreatic, breast, and prostate cancer cell
lines with little cytotoxicity to normal colon fibroblast cells (Thomas et al. 2012).
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Figure 3. Flavone structures (A) 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4H-chromen-4-one
(5, 7–dihydroxy- 3, 6, 8 trimethoxy flavone/ flavone A) from Gnaphalium elegans (B) 3,5dihydroxy-6,7,8-trimethoxy-2-phenyl-4H-chromen-4-one (3, 5–dihydroxy-6, 7, 8–trimethoxy
flavone/ flavone B) from Achyrocline bogotensis.
The mechanisms used by several flavonoids to achieve their anticancer effect involve the
induction of apoptosis (Chiang et al. 2006; Das et al. 2012; Ha et al. 2015; Hwang et al. 2005).
This can be accomplished by activating either the extrinsic or intrinsic pathway. The role of the
extrinsic pathway is to remove unwanted cells during development, and train the immune
system, as well as trigger immune-system-mediated tumor removal (Boatright and Salvesen
2003). The extrinsic pathway is activated by a ligand binding a death receptor such as the Fas or
TRAIL receptor, followed by binding of the Fas-associated protein with death domain (FADD)
to caspase 8. Subsequently, FADD is capable of activating caspase 8/10 which results in the
activation of the executioner caspase 3/7. The intrinsic pathway eliminates cells damaged by
ionizing radiation and chemotherapeutic drugs, as well as those with mitochondrial damage.
Certain developmental cues or decreased levels of active pro-survival proteins such as ERK, S6,
and BAD can also trigger the intrinsic pathway. Once the pathway is triggered, the mitochondrial
membrane is permeabilized by proapoptotic BAX or BAK, releasing cytochrome c. Caspase 9 is
14

then activated followed by the activation of caspase 3/7 (Boatright and Salvesen 2003; Cohen
1997; Nagata 1997). Although both flavone A and flavone B induce apoptosis, they use different
apoptotic pathways (LeJeune et al. 2015). Flavone A activates the intrinsic apoptotic pathway by
downregulating the active, phosphorylated forms of ERK, S6, and BAD. Dephosphorylated
BAD is then targeted to the mitochondria where it binds to BCL2 and BCL- XL and trigger
apoptosis (Chattopadhyay et al. 2001). Flavone B is able to activate the extrinsic pathway of
apoptosis via the concomitant increase of pERK and pc-JUN ultimately causing cell death
(LeJeune et al. 2015).
Although in vitro activity of flavone A and flavone B have been investigated, no studies
have been performed with either flavone in vivo. In order to determine a suitable dose for the in
vivo studies, the pharmacokinetics of a drug must be known. Pharmacokinetics is the study of
how the body acts on a drug (Shargel et al. 2005). This includes different aspects of metabolism,
absorption, distribution, and excretion of a drug. It is studied by taking blood samples at various
times prior and post dosing to determine the concentration of the drug in plasma. The plasma
concentration time profile can be used to determine parameters such as half-life (t 1/2 ), volume of
distribution (Vz), clearance (CL), and area under the curve (AUC). Tissue samples can be
collected to determine distribution of the drug, while urine, and feces samples can help determine
the rate and route of excretion.
The pharmacokinetic parameter half-life is the amount of time required for the
concentration of drug to decrease by half in plasma (Shargel et al. 2005). This information is
necessary to determine the frequency in which a drug needs to be administered. As the drug
travels through the body, a certain percentage may be distributed to the tissues. The volume of
distribution is used to determine the amount of drug that distributed throughout the body. Tissue
15

samples collected post dosing an animal can help determine which organs a drug is distributed to
and in what percent of the total drug concentration administered. The distribution patterns of a
drug can influence the effectiveness of drug used against a certain disease.
As the drug travels through the body it is broken down by metabolism and excreted by
the kidneys. Clearance is the rate at which this process occurs. Measuring the concentrations of
the drug in the urine and feces can help determine how much of the drug is cleared by excretion
and what percent of the drug is metabolized. Another parameter that is helpful in understanding
how the body affects the drug is the systemic exposure or the total concentration of drug in
plasma from administration to a set time post dosing or total elimination.
There are several different models to describe the pharmacokinetic of a drug (Shargel et
al. 2005). The simplest model is a one compartment open model which considers the body as one
container. The two compartment open model considers the blood, extracellular fluid, and highly
perfused tissues as one compartment while the tissues in which the drug equilibrates more slowly
is the second compartment. The three compartment open model adds bone and fat as a third
compartment to the two compartment model. Each pharmacokinetic parameter is calculated
slightly differently depending on the model in which the drug plasma concentration time profile
fits. These calculations can also be made using a noncompartment model which uses no
assumptions for a specific compartment model to analyze data.
In the studies described in chapters 2 and 3, rats were used to determine pharmacokinetic
parameters such as half-life, volume of distribution, clearance, area under the curve, and target
tissue concentration due to sensitivity of the HPLC method and their larger blood volume
compared to mice. Using rats allowed for the collection of blood samples at more time points to
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give us a better picture of the effect of the body on the flavones. Since flavone A and flavone B
have been reported to have antineoplastic activity against colon cancer in vitro (Thomas et al.
2012), colon tissues were collected to determine if the flavones distribute to the target organs
which would influence the effectiveness of these drugs as anticancer therapies and are discussed
in chapter 3.
The in vitro antitumor activity of these flavones against colon cancer is important
because it suggests possible activity in vivo. Colorectal cancer is the third most common type of
cancer found in both men and women in the United States. The American Cancer Society (ACS)
projects that 95,270 new cases of colon cancer will be diagnosed in 2016 and will result in
40,000 deaths (American Cancer Society 2016). Colon cancer can be detected at an early stage to
have a 90% five-year survival rate after treatment. However, 60% of colon cancer patients are
diagnosed after the cancer has spread to other organs, when the five year survival rate is found
to drop to 13% (American Cancer Society 2015).
The drastic difference in the five-year survival rates for colon cancer is due in part to the
ability to surgically remove cancerous tissue confined to the colon. However, once it has spread
to other part of the body, alternative forms of treatment including chemotherapy and radiation
are used to treat the disease (American Cancer Society 2016). The most commonly used
chemotherapy drug for colon cancer is the thymidylate synthase inhibitor, 5-fluorouracil (5-FU).
A metabolite of 5-FU, 5-fluoro-dUMP (FdUMP), binds with thymidylate synthase (TS) and
5,10-methylene-tetrahydrofolate (CH2-THF) preventing the conversion of dUMP to dTMP.
Without dTTP being added to the nucleotide pool, dUTP gets inserted into DNA instead. The
dTTP depletion also causes another 5-FU metabolite, 5-deoxyuridine triphosphate (FdUTP), to
also be incorporated into the DNA (Geng et al. 2011; Ghoshal and Jacob 1997; Peters et al.
17

2002). Unfortunately, the effect of 5-FU is not specific to cancer cells, and may result in several
side effects. This drug has a 10-20% response rate in colon cancer patients (Gu et al. 2013;
Longley et al. 2003; Rashid et al. 2014; Zhang et al. 2008).
The low five-year survival rate and low response rate of current therapies for colon
cancer warrant an urgent need for the development of new therapies. One strategy for increasing
the effectiveness of 5-FU is to add a secondary therapy with a different mechanism of action, in
order to increase the antineoplastic activity of the drug. Chapter 4 discusses the effect of using
flavone A or flavone B in combination with 5-FU against colon cancer in vitro and the
mechanism by which cell death is suggested to occur.
The pharmacokinetic studies discussed in chapter 3 determined that both flavone A and
flavone B distributed to the colon of the rats. These results indicated that both flavones were
good candidates for in vivo antitumor assays seeking to investigate the effect of the flavone on
colon cancer tumors. Over the years many different mouse models have been developed in order
to study different aspects of cancer. These models include xenografts of tumor cells, and
transgenic mice (Herreros-Villanueva et al. 2012). Some of these models are good for testing the
effect of a drug on tumor growth while others are better for testing tumor prevention or genetic
modifications in tumorigenic cells.
There are two different types of xenograft models, heterotopic and orthotopic (HerrerosVillanueva et al. 2012). The heterotopic model implants cancer cells between the muscle and
dermis of an immune compromised mouse. This can be done on the flank, shoulder, or foot pad
of the mouse. This is the most commonly used model for preclinical testing of anticancer drugs
due to the short time period required, and reproducibility. Furthermore, in this model the tumor
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is visible and can be easily measured to determine changes in tumor growth over time, or by
fluorescent imaging if the cancer cells used for the xenograft, have been fluorescently tagged.
The heterotopic xenograft model does have the disadvantage in that the cancer cells are
not located in the target organ. This causes changes in the microenvironment that can affect the
effectiveness of the drug. Differences in drug distribution can also cause changes in the effect of
a drug as a drug might get distributed to the subcutaneous tumor but not the target organ.
Another disadvantage of this model is that subcutaneous tumors rarely metastasize (Becher and
Holland 2006; Killion et al. 1998; Niedergethmann et al. 2007).
The orthotopic xenograft model injects cancer cells into the respective organ. The
advantage of this model is that the microenvironment and distribution of the drug are the same
for the tumor and target organ. In addition, these tumors are able to metastasize and site specific
studies for genes changes and drug therapy can be replicated. Unfortunately, this type of
xenograft is labor intensive, technically challenging, as well as expensive. This method takes
longer as there is a healing and recovery time. Since the tumors are not on the surface of the
animal, low throughput imaging is required to monitor changes in tumor volume
(Niedergethmann et al. 2007). Of the two xenograft models, the heterotopic option is good to use
in preclinical studies investigating the antitumor activity of a drug. However, the orthotopic
xenograft is better in studies investigating changes in gene expression and tumor metastasis in
response to therapy (Niedergethmann et al. 2007).
In this dissertation, the heterotopic xenograft model was used to determine the in vivo
antitumor activity of flavone B against colon cancer as well as the synergistic activity of flavone
B with 5-fluorouracil and is described in chapter 4.
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Abstract
Isomers 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4H-chromen-4-one (5,7–dihydroxy-3,6,8
trimethoxy flavone) (flavone A) and 3,5-dihydroxy-6,7,8-trimethoxy-2-phenyl-4H-chromen-4one (3,5–dihydroxy-6,7,8–trimethoxy flavone) (flavone B) have recently demonstrated
differential antineoplastic activities against pancreatic cancer in vitro. These studies also
indicated that these compounds target highly tumorigenic cells while sparing normal cells. The in
vivo antitumor activities of these flavones have not been determined, and detection protocols for
these compounds are needed to conduct pre-clinical assays following intravenous dosing. Here,
we report methods developed using acetonitrile to extract two flavone isomers and corresponding
internal standards, celecoxib and diclofenac, from rat plasma. Separation was achieved using a
Shimadzu liquid chromatography system with a C18 column and mobile phase acetonitrile/water
(60:40 and 70:30 for flavones A and B, respectively) containing 0.2% acetic acid and 0.05%
triethylamine at a flow rate of 0.4 mL/minute and detection at 245 nm. Calibration curves
ranging from 250-2,500 ng/mL and 2,500-100,000 ng/mL for both flavones were linear (r2 e
0.99) with the lower limits of quantification being 250 ng/mL. Recovery of concentrations 250,
1,000, 2,500, 5,000, and 100,000 ng/mL ranged from 87-116% and 84-103% (n=3) for flavone A
and B, respectively. Stability of both flavones after a freezing/thawing cycle yielded a mean peak
ratio e 0.92 when compared to freshly extracted samples. Intravenous administration of a 20
mg/kg dose in rats yielded half-lives of 83.68 ± 56.61 and 107.45 ± 53.31 minutes with clearance
values of 12.99 ± 13.78 and 80.79 ± 35.06 mL/min/kg for flavones A and B, respectively.

Keywords: 5, 7–dihydroxy- 3, 6, 8 trimethoxy flavone, 3, 5–dihydroxy-6, 7, 8–trimethoxy
flavone, flavonoids, cancer, HPLC, pharmacokinetics
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1. Introduction
Throughout history people have used plants for medicinal purposes. In the Andean mountains of
South America, people often rely on a group of plants commonly known as vira- viras to treat
different ailments (Thomas et al. 2012). Many of the bioactive compounds found in these plants
are part of a class of polyphenolic secondary metabolites called flavonoids, a large family of
compounds characterized by a C6-C3-C6 phenylbenzopyrone backbone. They are further
subclassified as flavones, isoflavones, flavanones, flavonols, anthocyanidins, and chalcones.
Over 5,000 flavonoids have been discovered, but the potential health benefit of only a few have
been studied (Cai et al. 2003). Pharmacological properties of flavonoids include antioxidant
(Benariba et al. 2013; Choudhary et al. 2008), antiviral (Lin et al. 2013; Zandi et al. 2012),
antidiabetic (Konate et al. 2014), as well as protective properties of the gastrointestinal tract
(Mota et al. 2009), and cardiovascular system (Middleton et al. 2000). Anticancer studies have
shown some flavonoids to prevent or inhibit the development of cancer in rodents (Ito et al.
2000; Kandaswami et al. 2005; Lambert 2013; Record et al. 1997; Yang et al. 2001). The
antineoplastic properties of flavonoids are due to their effect on cell growth, inhibition of kinase
activity, induction of apoptosis, suppression of the secretion of matrix metalloproteinases, and/or
tumor invasive behavior (Chiang et al. 2006; Dole•ková et al. 2012; Kandaswami et al. 2005).
Gnaphalium elegans and Achyrocline bogotensis are two of the species identified
generically as vira– viras that are traditionally used in the treatment of various cancers. A pair of
isomeric flavones, 5, 7–dihydroxy- 3, 6, 8 trimethoxy flavone (flavone A) and 3, 5–dihydroxy-6,
7, 8–trimethoxy flavone (flavone B) were isolated from bioactive fractions of G. elegans and A.
bogotensis respectively (Thomas et al. 2012; Torrenegra et al. 1980; Torrenegra et al. 1982;
Torrenegra et al. 1987). In vitro studies suggest that flavone A and flavone B have differential
antineoplastic activity against cancer cell lines, which may depend upon cellular tumorigenic and
22

differentiation status. Indeed, flavones A and B target cancer cell lines derived from colon,
pancreas, breast, and prostate that have been categorized as being highly tumorigenic. Among
these, flavone A demonstrated preferential activity against the better differentiated cell lines,
while flavone B was shown to be active against the poorly differentiated cells. Furthermore,
flavones A and B demonstrated significant cytotoxic activity on cancer cell lines of the pancreas
and the colon (Thomas et al. 2012).
Only 6% of the 46,420 new cases of pancreatic cancer projected to be diagnosed during
2014 will survive another 5 years. Of the 96,830 new cases of colon cancer predicted to be
diagnosed in 2014, only 40% will be detected at an early stage to have a 90% 5 year survival
rate. However, once the cancer has spread to distant organs, the 5 year survival rate drops to13%
(American Cancer Society 2014). Thus, new treatments for pancreatic and colon cancer are
urgently needed. In vivo testing and mechanistic analysis are warranted to further understand the
antineoplastic properties of these compounds.
In this study, we developed methods to quantify the concentration of flavone A or
flavone B in rat plasma, using high performance liquid chromatography (HPLC) analysis with
celecoxib or diclofenac as internal standards, respectively. These methods were used to
determine the pharmacokinetic parameters of flavone A and flavone B in rats administered a 20
mg/kg dose via intravenous injection.
2. Experimental
2.1 Chemicals and standards
5,7–dihydroxy- 3,6,8 trimethoxy flavone (flavone A) and 3,5–dihydroxy-6, 7,8–trimethoxy
flavone (flavone B) were extracted as described previously (Thomas et al. 2012). NMR analysis
was done to verify that compounds were e 99% pure in a Bruker 400MHz spectrometer
(Billerica MA). The results were compared to spectra previously obtained (Torrenegra et al.
23

1980; Torrenegra et al. 1982). Celecoxib was purchased from Toronto Research Chemicals
(Toronto, ON, CA). Diclofenac sodium was purchased from MP Biomedicals, LLC (Solon, OH).
HPLC grade acetonitrile, acetic acid, triethylamine and water were purchased from Fisher
Scientific (Pittsburgh, PA). Polyethylene glycol 400 was purchased from Electron Microscopy
Sciences (Hatfield, PA).

2.2 Stock solution and standards
Stock solutions of flavone A (100 µg/mL) and celecoxib (25 µg/mL) were prepared with
acetonitrile/water/acetic acid/triethylamine (60:40:0.2:0.05). Stock solutions of flavone B (100
µg/mL) and diclofenac (25 µg/mL) were prepared with acetonitrile/water/acetic
acid/trimethylamine, (70:30:0.2:0.05). All solutions were stored protected from light at 4 °C.

2.3 Sample preparation
Calibration curves for flavone A was prepared by spiking 100 µL of blank plasma with 100 µL
flavone A, 100 µL celecoxib (25 µg/mL), and 200 µL of organic solvent (acetonitrile). The
samples were vortex mixed for 5 seconds before centrifugation for 15 minutes at 4,400 rpm. The
supernatant was removed to a clean tube and evaporated using a Labconco vacuum concentrator
(Kansas City, MO). 200 µL of mobile phase was used to reconstitute the residue and 100 µL of
sample was injected into the HPLC column. Calibration curves for flavone B were prepared in
similar manner with diclofenac as the internal standard. Analysis was conducted in triplicate.

2.4 HPLC conditions and quantitation
Assays were performed with a Shimadzu liquid chromatography system (Shimadzu Scientific
Instruments Inc., Columbia, Maryland, USA) consisting of a DGU-20A Prominence degasser, of
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LC020AB solvent delivery system, SIL-20A HT auto sampler, CBM-20A communication bus
module, SPD-M20A diode array detector, and CTO-20A column oven with a C18 (100 × 4.6
mm, 2.6 µm; ACE, Aberdeen, Scotland) column. Mobile phases used were
acetonitrile/water/acetic acid/triethylamine 60:40:0.2:0.05 (for flavone A HPLC assay) and
70:30:0.2:0.05 (for flavone B HPLCassay). Detection was at 245 nm with a temperature of 30˚C.
Flow rate was 0.4 mL/minute with run times of 11 and 10 minutes respectively. LC solutions
program was used to collect and analyze the data. Plotting the peak area ratios of flavone against
internal standard in Excel were used to make the calibration curves.

2.5 Accuracy and precision
Calibration curves were used to determine the accuracy and precision of the methods. The
coefficient of variation (CV) of three replicates performed on the same day was used to
determine the precision for intra-day analysis and the CV of replicates performed on three
consecutive days was used for the precision of inter-day analysis. Accuracy was determined by
how close the calculated concentration was to the known concentration. Data is presented as
mean ± standard deviation.

2.6 Recovery
Five concentrations (250, 1,000, 2,500, 5,000 and 100,000 ng/mL) were used to determine the
percent of flavone recovered by the extraction method. Recovery was determined by comparing
the peak area ratio of extracted samples to the peak area ratio of non-extracted standard of the
same concentration. Experiment was performed in triplicate.
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2.7 Stability
Three concentrations (1,000, 5,000, and 100,000 ng/mL) were used to determine the stability of
the flavones after freezing/thawing cycle. 100 µL of blank plasma was spiked with 100 µL
flavone and put in -20 °C for 24 hours. After thawing, 100 µL of internal standard and 200 µL of
acetonitrile were added to the sample. Extraction was completed as describe above. The peak
area ratio of frozen samples was compared to the peak area ratio of freshly prepared samples.
Experiments were performed in triplicate.

2.8 Animals and drug administration
Male Sprague-Dawley rats weighting 269-305g and fitted with jugular vein cannulas were
purchased from Charles River (Raleigh, NC). Animals were housed in a 12 hour light-dark cycle
and experiments were carried out within the Animal Care Committee of East Tennessee State
University guidelines. During the experiment, rats were housed in metabolic cages. Flavones
were mixed in polyethylene glycol 400 and administered by intravenous injection to deliver a 20
mg/kg dose of flavone A (n=6) or flavone B (n=6). Serial blood samples (250 µL) were collected
at 0, 5, 15, 30, 60, 90, 120, 240, and 360 minutes post dosing. After 3 minutes of centrifugation
at 10,000 rpm, plasma collected and stored at -20 ˚C.

2.9 Pharmacokinetic analysis
Outliers were determined using SPSS Statistics software version 21. The non-compartmental
component of Phoenix WinNonlin (v.6.3) was used to calculate the pharmacokinetic parameters
such as clearance (CL), area under the plasma concentration-time curve from zero to t (AUC 0-t ),
area under the plasma concentration-time curve from zero to infinity (AUC
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0-•

), half-life (t 1/2 ),

and volume of distribution (Vz) for both flavones. A Student’s t-test was used to determine
statistical differences between the pharmacokinetic parameter of flavone A and B.

3. Results
3.1 Specificity
Chromatograms of blank plasma, blank plasma spiked with celecoxib, and blank plasma spiked
with celecoxib and flavone A are shown in Figure 1. Chromatograms of blank plasma, blank
plasma spiked with diclofenac, and blank plasma spiked with diclofenac and flavone B are
shown in Figure 2. The retention times for flavone A and celecoxib are 7.0 and 9.6 minutes,
respectively. Retention times for diclofenac and flavone B are 5.0 and 6.8 minutes, respectively.
Good separation was achieved and no interfering peaks were seen under these chromatographic
conditions.
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Figure 1. Elution of flavone A from plasma. HPLC chromatographs of (A) blank plasma; (B)
plasma spiked with internal standard (celecoxib 25 µg/ ml); (C) plasma spiked with flavone A
(100 µg/ml) and internal standard.
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Figure 2. Elution of flavone B from plasma. HPLC chromatographs of (A) blank plasma; (B)
plasma spiked with internal standard (diclofenac 25 µg/ml); (C) plasma spiked with internal
standard and flavone B (100 µg/ml).
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3.2 Linearity, lower limit, and precision
For both flavones, calibration curves were divided into 250-2,500 ng/mL and 2,500-100,000
ng/mL sections. The 2,500-100,000 ng/mL curve for flavone A has the representative calibration
equation of y = 0.000048x + 0.03024 while the 250-2,500 ng/mL curve has the representative
equation of y = 0.00005x + 0.01752 (Figure 3). Good linearity can be seen for flavone A with r2
= 0.9991 and r2 = 0.9917, respectively. For flavone B, the representative calibration equation for
the 2,500-100,000 ng/mL curve was y = 0.00006x while the 250-2,500 ng/mL curve equation
was y = 0.000148x + 0.00458 (Figure 4). These curves also had good linearity with r2 = 0.9994
and r2 = 0.9958, respectively. The lower limit of quantification (coefficient of variation < 40) for
both flavone A and B in plasma was 250 ng/mL (Tables 2 and 4).
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Figure 3. Calibration curves for flavone A extracted from plasma. Calibration curves were
made by graphing the flavone/internal standard area under the curve extracted from plasma
versus the known concentration of flavone A ranging from (A) 2,500-100,000 ng/mL or (B) 2502,500 ng/mL.
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Figure 4. Calibration curves for flavone B extracted from plasma. Calibration curves were
made by graphing the flavone/ internal standard area under the curve extracted from plasma
versus the known concentration of flavone B ranging from (A) 2,500-100,000 ng/mL or (B) 2502,500 ng/mL.
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Intra-day precision was determined by three calibrations curves performed in the same day.
Inter-day precision was determined by calibration curves performed on three consecutive days.
Intra-day coefficient of variation for flavone A (Tables 1 and 2) and B (Tables 3 and 4) were d
20.23 and d 39.94, respectively. The accuracy ranged from 94-112% for flavone A and 83-124%
for flavone B. Inter-day coefficient of variation for flavone A and B were d 22.44 and d 16.18
respectively. The accuracy ranged from 83-111% for flavone A and 89-103% for flavone B,
respectively.

Table 1. Intra-day and inter-day precision and accuracy for 2500-100000
ng/mL flavone A extracted from rat plasma
Concentration
Error intra-day
Observed intra-day
CV Accuracy
(ng/mL)
(%)
(n=3)
(%)
100000
25000
5000
2500

2.51 ± 1.82
4.43 ± 4.72
8.28 ± 6.29
17.38 ± 12.31

98830 ± 3277
24028 ± 1347
5126 ± 576
2774 ± 514

3.31
5.61
11.24
18.56

98
96
102
110

Concentration
(ng/mL)
100000
25000
5000
2500

Error inter-day
(%)
6.61 ± 4.28
9.17± 7.33
4.43 ± 3.85
12.53 ± 2.69

Observed inter-day
(n=3)
103582 ± 8033
26843 ± 2481
4898± 308
2186 ± 67

CV

Accuracy
(%)
103
107
97
87
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7.75
9.24
6.29
3.07

Table 2. Intra-day and inter-day precision and accuracy for 250-2500 ng/mL
flavone A extracted from rat plasma
Concentration
Error intra-day
Observed intra-day
CV Accuracy
(ng/mL)
(%)
(n=3)
(%)
2500
1000
500
250

3.54 ± 1.83
12.53 ± 11.32
11.25 ± 10.94
12.61 ± 13.26

2494 ± 117
1125 ± 113
516 ± 85
236 ± 48

4.71
10.06
16.57
20.23

99
112
103
94

Concentration
(ng/mL)

Error inter-day
(%)

Observed inter-day
(n=3)

CV

Accuracy
(%)

2500
1000
500
250

5.92 ± 3.39
15.07 ± 12.65
11.75 ± 13.59
16.54 ± 9.02

2509 ± 199
996 ± 223
558± 68
208 ± 23

7.96
22.44
12.17
11.03

100
99
111
83

Table 3. Intra-day and inter-day precision and accuracy for 2500-100000
ng/mL flavone B extracted from rat plasma
Concentration
Error intra-day
Observed intra-day CV
Accuracy
(ng/mL)
(%)
(n=3)
(%)
100000
3.71 ± 2.52
103140 ± 3497
3.39
103
25000
4.16 ± 2.35
23958 ± 588
2.46
96
5000
9.68 ± 3.36
4515 ± 168
3.73
90
2500
9.71 ± 2.22
2257 ± 56
2.48
90
Concentration
(ng/mL)
100000
25000
5000
2500

Error inter-day
(%)
3.11 ± 3.18
4.89 ± 2.64
10.88 ± 4.61
10.51 ± 9.30

Observed inter-day
(n=3)
104648 ± 2355
25450 ± 1999
4781 ± 334
2223 ± 149

34

CV
2.28
7.84
6.98
6.7

Accuracy
(%)
103
102
96
89

Table 4. Intra-day and inter-day precision and accuracy for 250-2500 ng/mL
flavone B extracted from rat plasma
Concentration
Error intra-day
Observed intra-day
CV
Accuracy
(ng/mL)
(%)
(n=3)
%
2500
8.28 ± 2.11
2535 ± 255
10.07
101
1000
7.43 ± 5.77
1068 ± 67
6.28
106
500
24.31 ± 17.38
621 ± 87
13.98
124
250
20.95 ± 29.27
209 ± 83
39.94
83
Concentration
(ng/mL)

Error inter-day
(%)

Observed inter-day
(n=3)

CV

Accuracy
%

2500
1000
500
250

4.56 ± 3.42
4.51 ± 4.83
10.86 ± 9.03
9.20 ± 9.42

2527 ± 160
1027 ± 65
487 ± 79
259 ± 35

6.35
6.35
16.18
13.4

101
102
97
103

3.3 Recovery
Recovery was determined by comparing the peak area ratio of extracted sample to peak area
ratio for non-extracted standards of specific concentration (250, 1,000, 2,500, 5,000, and 100,000
ng/mL). This experiment was performed in triplicate with mean recovery ranging 87-116% for
flavone A and 84-102% for flavone B, respectively (Tables 5 and 6).

Table 5. Recovery of flavone A
extracted from rat plasma
Concentration Recovery
RSD
(ng/mL)
(%)
(%)
100000
87
4.01
5000
102
6.02
2500
106
8.70
1000
116
10.04
250
92
25.40
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Table 6. Recovery of flavone B
extracted from rat plasma
Concentration Recovery
RSD
(ng/mL)
(%)
(%)
100000
92
3.10
5000
102
1.78
2500
84
15.20
1000
103
7.92
250
101
4.11
3.4 Stability
Stability was determined by comparing the peak area ratio of spiked plasma that had been frozen
with peak area ratio of samples that had been freshly prepared for concentrations 1,000, 5,000,
and 100,000 ng/mL. This experiment was performed in triplicate with mean peak ratio ranging
from 0.93-1.04 for flavone A and 0.92-1.09 for flavone B, respectively (Table 7).
Table 7. Stability of flavone A and flavone B in rat plasma after
freeze/thaw cycle (n=3)
Flavone A
Flavone B
Concentration Mean peak
RSD
Concentration Mean peak
(ng/mL)
area ratio
(%)
(ng/mL)
area ratio
100000
5000
1000

1.01
0.93
1.04

4.82
18.68
25.84

100000
5000
1000

1.05
1.09
0.92

RSD
(%)
3.61
3.53
5.29

3.5 Pharmacokinetics of flavones A and B following a single intravenous injection
The plasma concentration-time profile for flavone A after the administration of a 20 mg/kg dose
via intravenous injection is shown in Figure 5A. The pharmacokinetic parameters are listed in
Table 8. Flavone A has a short half-life of 83.68 ± 56.61 minutes and clearance of 12.99 ± 13.78
mL/min/kg. The plasma concentration-time profile and pharmacokinetic parameters for flavone
B after the intravenous administration of a 20 mg/kg dose are shown in Figure 5B and table 9.
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The half-life of flavone B is calculated to be 107.45 ± 53.31 minutes with a clearance of 80.79 ±
35.06 mL/min/kg.

Figure 5. Area under the plasma concentration-time (AUC) curves. AUC following
intravenous administration of 20 mg/kg doses of (A) flavone A or (B) flavone B.
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Table 8. Pharmacokinetic parameters of flavone A after
administration of a 20 mg/kg dose via intravenous
injection (n=6)
Parameters
Values
t 1/2 (min)
83.68 ± 56.61
Vz (mL/kg)
986.77 ± 591.30
CL (mL/min/kg)
12.99 ± 13.78
AUC 0-360 (µg*min/mL)
2358.14 ± 1200.70
AUC 0-• (µg*min/mL)

2492.82 ± 1244.27

Legend: t 1/2 - half-life, V Z – volume of distribution,
CL – total clearance, AUC 0-t – area under the plasma
concentration-time curve from 0 to 360 minutes,
AUC 0-• - area under the plasma concentration-time
curve from time 0 to infinity.
Table 9. Pharmacokinetic parameters of flavone B after
administration of a 20 mg/kg dose via intravenous
injection (n=6)
Parameters
Values
t 1/2 (min)
107.45 ± 53.31
Vz (mL/kg)
11463.50 ± 5936.69
CL (mL/min/kg)
80.79 ± 35.06
AUC 0-240 (µg*min/mL)
245.47 ± 112.47
AUC 0-• (µg*min/mL)

289.14 ± 121.58

Legend: t 1/2 - half-life, V Z – volume of distribution,
CL – total clearance, AUC 0-t – area under the plasma
concentration-time curve from 0 to 240 minutes,
AUC 0-• - area under the plasma concentration-time
curve from time 0 to infinity.
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4. Discussion
Our previous studies have shown that isomeric flavones A and B have significant antineoplastic
activity against highly tumorigenic pancreatic and colon cancer cell lines with varying
differentiation status (Thomas et al. 2012). In the current study, we developed simple HPLC
methods to determine the concentration of either flavone A or B in rat plasma. The methods
described in this paper provide good separation of the flavones from the plasma peaks and
internal standards. To optimize our methods, several ratios of acetonitrile and water of differing
pH were used to achieve separation from the plasma peak. Also, a variety of compounds were
tested to determine the most appropriate internal standards, including flavonoids, vitamins,
statins, and nonsteroidal anti-inflammatory drugs. Most compounds, especially the flavonoids,
overlapped with the drug or the plasma peak. Celecoxib and diclofenac gave the best peaks
without overlapping, as well as good run times close to 10 minutes (Figures 1 and 2).
The described assays provide satisfactory and reproducible quantification of the flavones
in concentrations ranging from 250-100,000 ng/mL (Tables 1-4). The assays were linear for both
flavone A and flavone B (Figure 3). The extraction method used yielded satisfactory, consistent
recovery for both flavones at all concentrations (Tables 5 and 6). Freezing and thawing of spiked
plasma samples showed that both flavones were not degraded during the process (Table 7).
Both flavone A and B have short half-lives (< 120 minutes) that are commonly seen in
flavonoids (Talbi et al. 2014; Yang et al. 2014; Zhang et al. 2014; Zhu et al. 2015). The area
under plasma concentration-time profiles shows that flavone B disappears from the plasma at a
faster rate than flavone A (Figure 5). The concentrations of flavone B were below the limits of
detection (250 ng/mL) by 360 minutes, whereas flavone A was still detectable at that time. This
difference in plasma levels was also seen in the AUC 0-• values (p = 0.0015) depicted in tables 8
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and 9. These observations correspond with the higher volume of distribution (p = 0.0015) and
higher clearance (p = 0.0013) values of flavone B compared to those of flavone A. Part of the
observed rapid disappearance of flavone B in plasma could be explained by the higher lipophilic
nature of this flavone (Thomas et al. 2012). This is further supported by reports that flavonoids
can be incorporated into the erythrocyte cell membrane causing an echinocytic form of these
cells, and into epithelial cell membranes (Bonarska-Kujawa et al. 2014; Pawlikowska-Pawlega et
al. 2014). The lipophilic nature of the compounds may also favor their rapid distribution into
tissues.

5. Conclusion
Extraction methods were developed for flavones A and B from rat plasma that have been
validated in terms of recovery, linearity, precision, and accuracy. The HPLC methods developed
for flavones A and B have good separation and detection for the ranges of 250-100,000 ng/mL.
Pharmacokinetic analysis of flavone A and B reveal them to have short half-lives comparable to
other flavonoids.
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CHAPTER 3
QUANTIFICATION OF TWO ISOMERIC FLAVONES IN RAT COLON TISSUE USING
REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Introduction
Many flavonoids have been recognized for their antitumor properties (Kale et al. 2008;
Kandaswami et al. 2005; Lopez-Lazaro 2002; Wang 2000). It is known that these activities are
greatly determined by their chemical structure which subsequently dictates their ability to
interact with cellular molecules (Lopez-Lazaro 2002). This differential effect has been observed
with flavone isomers flavones 5,7–dihydroxy-3, 6, 8–trimethoxy flavone (flavone A) and 3, 5–
dihydroxy-6, 7, 8–trimethoxy flavone (flavone B) (Thomas et al. 2012). Specifically, each
isomer has been shown to target colon cancer cells with distinct phenotypical characteristics via
different mechanisms of action (LeJeune et al. 2015). However, it is unknown whether either of
these flavones distribute to the colon after intravenous administration of these compounds.
Modifications were made to methods developed for extracting and quantifying these flavones in
rat plasma using reverse phase high performance liquid chromatography. The modifications
included preparation of the sample by homogenization in water and filtration using a
polyvinylidene fluoride (PVDF) membrane, and the creation of calibration curves to determine
the concentration of either flavone in colon tissue.
These methods allowed for the detection of flavone A and flavone B in rat colon. Our
data indicate that flavone B was found in higher concentrations in the colon than flavone A,
which may be the result of higher volume of distribution value of flavone B (Whitted et al. 2015)
compared to that of flavone A.
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Method and Results
Procedure to extract and purify flavones A and B
The compounds were obtained as described before (Thomas et al. 2012). Briefly, flavone
A was purified from dried flowers of Gnaphalium elegans extracted with chloroform using a
silica gel chromatography column. Flavone B was purified from leaves of Achyrocline
bogotensis, using chloroform, followed by crystallizations in hexane. The physical and
spectroscopic properties of these compounds allowed their proper identification.

Stock solution and standards
Stock solutions of flavone A at a concentration of 100 µg/mL, prepared as described
previously (Whitted et al. 2015), and 25 µg/mL celecoxib (Toronto Research Chemicals;
Toronto, ON, CA) were prepared with acetonitrile/water/acetic acid/triethylamine
(60:40:0.2:0.05). Stock solutions of 100 µg/mL of ﬂavone B, prepared as described
previously(Whitted et al. 2015), and 25 µg/mL diclofenac (MP Biomedicals, LLC; Solon, OH)
were prepared with acetonitrile/water/acetic acid/trimethylamine (70:30:0.2:0.05). All stock
solutions were stored protected from light at 4ºC. HPLC grade acetonitrile, acetic acid,
trimethylamine, and water were purchased from Fisher Scientiﬁc (Pittsburgh, PA). Flavone A or
flavone B were mixed with polyethylene glycol 400 (Electron Microscopy Sciences; Hatﬁeld,
PA) for intravenous injection.

Sample preparation
Colon tissue was homogenized using a PowerGen 700 from Fisher Scientific (Pittsburgh,
PA) in a 1:2 ratio with water (1 mg/ 2 mL). Serial concentrations for calibration curves (ﬂavone
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A: 250-100000 ng/g and flavone B: 1000-25000 ng/g) were prepared. Briefly, 100 µL of blank
homogenate was spiked with 100 µL ﬂavone, 100 µL internal standard (25 µg/mL celecoxib or
diclofenac), and 200 µL of organic solvent (acetonitrile). The samples were vortex mixed before
being centrifuged for 15 min at 3000 x g. The supernatant was removed and filtered with a
polyvinylidene fluoride (PDVF) filter (0.45 µm) into a clean tube and evaporated using a
Labconco vacuum concentrator (Kansas City, MO). Mobile phase (200 µL) was used to
reconstitute the residue and 100 µL of sample was injected into the HPLC column. Analysis was
conducted in triplicate.

HPLC conditions and quantitation
HPLC assays were performed using a Shimadzu liquid chromatography system
(Shimadzu Scientiﬁc Instruments Inc., Columbia, Maryland, USA) with an ACE C18 (100×4.6
mm) (Aberdeen, Scotland) column. Mobile phases used for HPLC contained acetonitrile/water
60:40 (ﬂavone A) and 70:30 (ﬂavone B) with 0.2% acetic acid and 0.05% triethylamine.
Detection wavelength was at 245 nm with a temperature of 30 ºC. Flow rate was 0.4 mL/min
with run times of 11 and 10 min, respectively. LC solutions program was used to collect and
analyze the data. Good separation was achieved (Figures 1 & 2) and the peak area ratios of
ﬂavone against internal standard were plotted in Excel to make the calibration curves (Figure 3).
Representative equation for flavone A concentrations 250–100000 ng/g was y = 2E-05x +
0.0029 and flavone B concentrations 1000-25000 ng/g was y = 7E-05x + 0.0531 with r2 e 0.99.
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Figure 1. Elution of flavone A from colon. HPLC chromatographs of (A) blank colon; (B) colon
spiked with internal standard (celecoxib 25 µg/mL); (C) colon spiked with flavone A (100
µg/mL) and internal standard.
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Figure 2. Elution of flavone B from colon. HPLC chromatographs of (A) blank colon; (B) colon
spiked with internal standard (diclofenac 25 µg/mL); (C) colon spiked with flavone B (100
µg/mL) and internal standard.
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Figure 3. Calibration curves were made by graphing the ratio of ﬂavone/internal standard area
under the curve extracted from colon tissue versus the known concentration of ﬂavone.
Representative calibration curves for (A) flavone A and (B) flavone B are presented.

Precision and accuracy
Three calibration curves were used to determine the precision (coefﬁcient of variation CV) and accuracy of the methods. Data is presented as mean ± standard deviation (Tables 1 &
2).

Table 1. Precision and accuracy for 250-100000 ng/g flavone A
extracted from rat colon tissue
Concentration
Error
Observed
CV Accuracy
(%)
(ng/g)
(%)
(n=3)
100000
13.88 ± 2.14 113888 ± 2138
1.87
114
25000
16.32 ± 1.06
29081 ± 265
0.91
116
11.83 ± 4.15
11182 ± 415
3.71
111
10000
5000
9.93 ± 0.97
5496 ± 48
0.88
109
2500
13.92 ± 4.87
2848 ± 121
4.27
113
1000
11.45 ± 8.90
1114 ± 89
7.98
111
16.65 ±
500
558 ±129
23.21
111
21.51
21.02 ±
250
285 ± 68
24.03
113
19.30
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Table 2. Precision and accuracy for 1000-25000 ng/g flavone B
extracted from rat colon tissue
Concentration
Error
Observed
CV Accuracy
(%)
(ng/g)
(%)
(n=3)
25000
1.51 ± 0.50
25204 ± 410
1.62
101
2.89 ± 0.52
10075 ± 345
3.43
101
10000
5000
3.69 ± 3.42
4934 ± 271
5.51
98
2500
4.22 ± 2.55
2480 ± 142
5.73
99
25.18 ±
1000
1128 ± 378
33.56
113
27.00
Animals and drug administration
The methods described here were used to determine the concentrations of flavone A or
flavone B in colon tissue collected from the male Sprague-Dawley rats used in a previous study
(Whitted et al. 2015). Briefly, flavones were mixed in polyethylene glycol 400 and were
administered by intravenous injection to deliver a 20 mg/kg dose of ﬂavone A (n=6) or ﬂavone B
(n=6). Animals were euthanized under anesthesia 6 hours post dosing. Colon tissue was collected
and flash frozen using dry ice and stored at -80 ºC until analyzed for the measurement of
concentrations of flavones. Analysis yielded 1639 ± 601 ng/g of flavone A and 5975 ± 2480 ng/g
of flavone B in colon tissue (Figure 4).
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Figure 4. Distribution of flavones to target tissue. Male Sprague-Dawley rats received 20 mg/kg
of either flavone A or flavone B via intravenous injection. The colon tissues were collected 6
hours after dosing and analyzed for the presence of flavone using a HPLC system.

Discussion
The modifications made to the methods for extracting flavone A and flavone B from rat
plasma enabled the development of good methods for extracting and quantifying these flavones
from rat colon tissue. The in vitro antineoplastic activity of these flavones against colon cancer
cells in combination with both flavones distributing to rat colon tissue makes them good
candidates for in vivo experiment investigating their antitumor activity against colon cancer.
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CHAPTER 4
THE EFFECT OF TWO ISOMERIC FLAVONES, 5-FLUOROURACIL, AND
COADMINISTRATION AGAINST COLON CANCER

Introduction
The American Cancer Society lists colorectal cancer as the second leading cause of death
in the United States and estimates that 49,190 death will result from colon cancer alone in 2016
(American Cancer Society 2016). Colon cancer has a 90% five-year survival rate if diagnosed
early. Unfortunately, this is expected to only occur for 40% of the 95,270 new cases of colon
cancer that are predicted to be diagnosed in 2016. Once the cancer has metastasized to distant
organs, the five- year survival rate drops to 13% (American Cancer Society 2015).
Surgery is the most common treatment for localized colon cancer. Once the cancer has
spread, chemotherapy is often used (American Cancer Society 2015). 5-fluorouracil (5-FU) has
been used to treat a wide variety of cancers including that of the colon for the last 50 years
(Rashid et al. 2014; Srimuangwong et al. 2012).
5-fluoro-dUMP (FdUMP), the main active metabolite of 5-FU, forms a complex with
thymidylate synthase (TS) and 5,10-methylene-tetrahydrofolate (CH2-THF) preventing dUMP
be converted to dTMP causing a depletion of dTTP from the nucleotide pool. This depletion
allows for the insertion of dUTP and another 5-FU metabolite, 5-deoxyuridine triphosphate
(FdUTP), into DNA (Figure 1A), (Geng et al. 2011; Ghoshal and Jacob 1997; Peters et al. 2002).
The DNA damage caused by dUTP and FdUTP triggers Ataxia-telangiectasia mutated and Rad3-
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related (ATR) kinase cascade resulting in cell cycle arrest and apoptosis (Figure 1B and C)
(Flynn and Zou 2011; Woods and Turchi 2013).
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Figure 1. Mechanism of action of 5-fluorouracil. (A) A metabolite of 5-FU (FdUMP) binds TS to
delete dTTP from the nucleotide pool. (B) Ataxia-telangiectasia mutated and Rad3-related ATR
response to DNA damage. (C) Cellular response to 5-FU induced DNA damage leading to
apoptosis.
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Unfortunately, the activity of 5-FU is not cancer cell specific, resulting in several side
effects and only has a 10-20% response rate in colon cancer patients (Gu et al. 2013; Longley et
al. 2003; Rashid et al. 2014; Zhang et al. 2008). One method to try to improve the effectiveness
of 5-FU is to include a secondary drug with the treatment (Cheah et al. 2014; Gonzalez-Vallinas
et al. 2013; Wang et al. 2014a).
The two isomeric flavonoids, flavone A, and flavone B which are isolated from
Gnaphalium elegans and Achyrocline bogotensis, have been shown by our laboratory to have
differential antineoplastic activity against colon cancer (Thomas et al. 2012). Flavone A is
cytotoxic to more differentiate CaCo 2 colon cancer cells, while flavone B is effective against the
poorly differentiate HCT 116 colon cancer cells. In this chapter, we investigate the mechanisms
by which the flavones may cause synergistic effects on colon cancer cell lines when used in
combination with 5-FU in vitro and in vivo.
Methods
Chemicals
Flavone A and flavone B were obtained as previously described (Thomas et al. 2012).
Briefly, flavone A was extracted from G. elegans dried flowers using CHCl 3 then concentrated
by dry vacuum. Methanol and filtering were used to remove fats and hydrocarbons from the
residue. The concentrated residue was reconstituted in C 6 H 6 and eluted by silica gel
chromatography using C 6 H 6 :Me 2 CO (19:1) as a mobile phase. The flavonoid was purified by
crystallizations in hexane. Physical and spectroscopic properties of 5,7 dihydroxy-3,6,8
trimethoxyflavone, were used for identification of the compound. Flavone B was extracted by
soaking fresh leaves of A. bogotensis in CHCl 3 followed by filtration and concentration. The
residue dissolved in hot methanol. Fats and hydrocarbons were filtered out of the sample before
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reconcentration. Hexane was used to dissolve and recrystallize the purified flavonoid. Physical
and spectroscopic properties as 3,5-dihydroxy-6,7,8-trimethoxyflavone were used to identify the
compound. Stock solutions of flavones were prepared using dimethyl sulfoxide to yield a
maximum final concentration of 0.01% in the treated well (Sigma-Aldrich, St. Louis, MO). 5fluorouracil (5-FU) was purchased from Sigma Aldrich (St Louis, MO).
Cell culture
Colon cancer cells lines HCT 116 and CaCo 2 were purchased from American Tissue
Type Culture Collection (ATCC; Manassas, VA). HCT 116 cells were culture in McCoy’s media
and CaCo 2 cells cultured in DMEM/F12 media (GIBCO/Invitrogen, Carlsbad, CA). Media was
supplemented with 10% fetal bovine serum (GIBCO/Invitrogen, Carlsbad, CA) and 1%
penicillin/streptomycin (Hyclone, Logan, UT). DMEM/F12 was also supplemented with 1%
sodium pyruvate (Hyclone, Logan, UT).
Cell viability assay
HCT 116 and CaCo 2 cells were seeded in 48 well plates and grown until ~75%
confluent. CaCo 2 cells were treated with either dissolution vehicle (DMSO), flavone A (5-80
µM), 5-FU (5-80 µM) (Cheah et al. 2014; Hwang et al. 2005; Riahi-Chebbi et al. 2015), or
combination (5-FU 5-80 µM and 40 µM flavone A). HCT 116 cells were treated with either
vehicle, flavone B (5-80 µM), 5-FU (5-80 µM), or combination (5-FU 5-80 µM and 40 µM
flavone B). Cells were incubated at 37 ºC for 48-72 hours. 3-(4, 5-methyl-thiazol-2-yl)-2, 5diphenyl-tetrazolium bromide (MTT) was added at 10% per volume and incubated for 3 hours
(Invitrogen). Formazan crystals were solubilized with acidified 2-propanol and optical density
was measured at 570 nm using a Biotek PowerWave XS2 plate reader (Winooski, VT).
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Statistical analysis was performed using One-way ANOVA (Tukey) on Graph Pad v5.
Combination index was determined using CompuSyn.
Effect = 100- viability

(1)

CI = [a]/[A] + [b]/[B]

(2)

a = concentration of individual drug 1 to achieve X effect. A = concentration of drug 1 in
combination to achieve effect X. b = concentration of individual drug 2 to achieve X effect. B =
concentration of drug 2 in combination to achieve effect X.
Apoptosis assay
Cells were plated on coverslips and grown until ~75% confluent. CaCo 2 cells were
treated with vehicle, 40 µM flavone A, 80 µM 5-FU, or combination. HCT 116 cells were treated
with vehicle, 40 µM flavone B, 80 µM 5-FU, or combination. After 24-72 hours of treatment,
TUNEL assay (TdT-mediated dUTP nick end labeling) was performed as directed by the
manufacturer (Roche; Mannheim, Germany). Briefly, the cells were fixed with 4%
paraformaldehyde and permeabilized with 0.1% sodium citrate and 0.1% Triton. TUNEL reagent
was then added. Nuclei of the cells were stained with DAPI. Fluorescence microscopy images
were obtained using an EVOS microscope (AMG, Bothell, WA).
Cell cycle analysis
CaCo 2 or HCT 116 cells were grown in 6 well plates until ~75% confluent. Cells were
treated with flavone (40 µM), 5-FU (80 µM), or combination. Cells were lifted with cell scraper
and suspended in binding buffer for cell cycle and apoptosis quantification using an Annexin VFITC kit from Abcam (Cambridge, MA) according to manufacturer instructions. Briefly,
Annexin and propidium iodide were added to suspended cells and incubated in the dark for 5
minutes. A BD Accuri C6 flow cytometer (BD Bioscience, San Jose, CA) was used to obtain cell
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count. Data was analyzed with CFLOW Plus (BD Bioscience, San Jose, CA). One-way ANOVA
(Tukey) was performed using Graph Pad v5 for statistical analysis.
Comet assay
Caco 2 and HCT 116 cells were plated in 6 well plates and grown until ~75% confluent.
CaCo 2 cells were treated with vehicle, flavone A (40 µM), 5-FU (80 µM), or combination. HCT
116 cells were treated with vehicle, flavone B (40 µM), 5-FU (80 µM), or combination. Cells
were lifted from the plate using a cell scraper and suspended in 300 µL phosphate buffered
saline. Alkaline comet assay (Trevigen, Gaithersburg, MD) was performed per manufacturer’s
instructions. Briefly, cells were suspended in agarose and plated in comet plates. Cells were
lysed with lysing buffer then immersed in alkaline unwinding solution. Samples were washed
with deionized water and 70% ethanol. SYBR gold (Life Technologies, Eugene, OR) was used
to stain the cells. Fluorescence microscopy images were obtained using an EVOS microscope
(AMG, Bothell, WA). Tail moment (tail length * percent tail DNA) (Gyori et al. 2014) was
determined using the OpenComet plugin for Image-J (NIH). Tail moments > 5 were used to
determine average tail moments for 50 + samples. One-way ANOVA (Tukey) was performed
using Graph Pad v5 for statistical analysis.
Antibodies
Antibodies pCHK1 (S345), CHK1, pBAD (S112), BAD, P-p44/42 MAPK (T202), p44/42
MAPK (ERK ½), and BCL-2 were purchased from Cell Signaling (Beverly, MA), ² -actin from
Sigma (St. Louis, MO), TS from Santa Cruz (Dallas, TX), ³ -H2AX from Bethyl Laboratories
(Montgomery, TX), Cleaved Caspase 3 (Asp 175) (R & D Systems, Minneapolis, MN), and
Alexa Fluor 594 goat anti-rabbit IgG (GIBCO/Invitrogen, Carlsbad, CA). Peroxidase-conjugated
secondary antibodies were affinity purified with no cross-reactivity with other species and
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obtained from Pierce (Rockford, IL), Promega (Madison, WI), and Jackson ImmunoResarch
(West Grove, PA).
Immunoblot
HCT 116 and CaCo 2 cells were treated in the same manner as for apoptosis assay and
lysed after 4-32 hours using lysis buffer consisting of 20 mM imidazole, 100 mM KCl, 1mM
MgCl 2 , 10mM EGTA, 0.2% Triton X-100, phosphatase, and protease inhibitors (Sigma
Aldrich). A protein assay from Cytoskeleton (Denver, CO, USA) was used to measure protein
concentrations from cell lysates and the colorimetric reaction was read spectrophotometrically at
590nm (Cary 50; Varian, Palo Alto, CA). The samples were run in SDS-PAGE and then blotted
onto nitrocellulose membranes. The signal of the primary antibodies was detected using
secondary affinity-purified goat anti-mouse or anti-rabbit immunoglobulins coupled to
peroxidase and a chemiluminescent system (Pierce; Grand Island, NY) and images obtained
using a gel documentation system (G:Box fromSyngene, Frederick, MD). The intensity of the
bands in the images were estimated after subtracting the background and compared against a
control using Image J (NIH). One-way ANOVA (Tukey) was performed using Graph Pad v5 for
statistical analysis.
Immunofluorescence
HCT 116 and CaCo 2 cells were plated on coverslip until ~75% confluent. HCT 116 cells
were treated with vehicle, flavone B (40 µM), 5-FU (80 µM), or combination for 48 hours. CaCo
2 cells were treated with vehicle, flavone A (40 µM), 5-FU (80 µM), or combination for 36
hours. Cells were fixed with 3% paraformaldehyde and incubated with cleaved Caspase 3 (A175)
antibody (R & D Systems, Minneapolis, MN). Alexa Fluor 594 goat anti-rabbit IgG

59

(GIBCO/Invitrogen, Carlsbad, CA) was used as secondary antibody and cells were counted
stained with DAPI. Images were taken using an EVOS microscope (AMG, Bothell, WA).
Animals and drug administration
Male NCrNU immunodeficient mice were obtained from Taconic (Hudson, NY) and
were housed in a sterile room with a 12 hour light-dark cycle. All experiments were carried out
following the guidelines of the Animal Care Committee of East Tennessee State University.
Mice were injected in the right flank with 5 x 106 HCT116 cells in matrigel. After tumors
reached an average of 5 x 5 mm, mice were divided into 4 groups (n=6). Group 1 was treated
with polyethylene glycol 400 given by intratumoral (IT) injection and saline given by
intraperitoneal (IP) injection once a day, three days a week. Group 2 was administered 1 mg/kg
flavone B in polyethylene glycol 400 by IT once a day, three days a week. Group 3 was
administered 12 mg/kg 5-FU in saline by IP once a day, three days a week. Group 4 was
administered flavone B via IT and 5-FU via IP once a day, three days a week. The weight of
mice and tumor size were measured three times a week. Tumor volume (TV) was calculated
using length and width measurement of the tumor.
TV = d2 * D/2

(3)

With d being the smaller diameter and D the larger diameter. Relative tumor volume (RTV) was
calculated as ratio of tumor volume to average control tumor volume. Animal were euthanized
under anesthesia and tumors were collected. Two-way ANOVA (Tukey) was performed using
Graph Pad Prism for statistical analysis.
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Results
Flavone A and flavone B have synergistic activity on colon cancer cells when used in
combination with 5-fluorouracil.
To determine whether the addition of flavone A or flavone B to cells treated with 5–FU
will produce an increase in cytotoxicity, colon cancer cells were treated with each agent alone
and in combination and analyzed for cell viability. A single dose of flavone in the middle of the
concentration consistent to the one used in the previous study which caused loss of cell viability
e 50% was used in the combination treatments (Thomas et al. 2012). Caco 2 cells were treated
with 0, 5, 10, 20, 40, or 80 µM flavone A, 5-FU, or combination (40 µM flavone A and 5-80 µM
5-FU). After 48 hour MTT assay was performed to determine cell viability. Cells treated with
either flavone A or 5-FU individually had cell viability similar to that of the controls. However,
the combination treatment was able to decrease cell viability to below 50% (Figure 2A). The
combination index (CI) was calculated using CompuSyn to determine if the increased
cytotoxicity seen with the combination treatment was additive (CI=1), antagonistic (CI>1), or
synergistic (CI<1). The effect for all concentration combinations of flavone A and 5-FU used
were found to be synergistic (Figure 2B).
HCT 116 cells were treated with 0, 5, 10, 20, 40, or 80 µM flavone B, 5-FU, or
combination (40 µM flavone B and 5-80 µM 5-FU) for 72 hours. Flavone B and 5-FU had
similar effects on cell viability with the lowest cell viability around 65% (Figure 2C). The
combination treatment was more cytotoxic against HCT 116 cells causing cell viability to
decrease to 38% with the highest concentration. All concentration combinations of flavone B
and 5-FU were synergistic (Figures 2D).
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Figure 2. Combination treatment decreases cell viability of colon cancer cells. (A) Cell viability
of colon cancer cells, CaCo 2, treated with flavone A, 5-fluorouracil, or combination for 48
hours. (B) Combination index comparing the effect achieved by concentration of drug(s) in
combination versus individual treatments of 5-fluorouracil and/or flavone A on CaCo 2 cells. (C)
Cell viability of colon cancer cells, HCT 116, treated for 72 hours with flavone B, 5-fluorouracil,
or combination. (D) Combination index comparing the effect achieved by concentration of
drug(s) in combination versus individual treatments of 5-fluorouracil and/or flavone B on HCT
116 cells. Cell viability was determined using MTT assay. * Significant difference (p < 0.05
determined using One-way ANOVA (Tukey).

Combination treatment increases the induction of apoptosis in CaCo 2 cells.
Both flavones and 5-FU have been shown to induce apoptosis (Thomas et al. 2012; Wang
et al. 2014a) TUNEL assay was performed to determine if the combination treatment increased
the induction of apoptosis versus the individual treatments. CaCo 2 cells were treated with 40
µM flavone A, 80 µM 5-FU, or combination. After 24 or 36 hours, TUNEL assay was
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performed. At 24 hours apoptosis could be detected in cells treated with flavone A, but not 5-FU
or the combination treatment (Figure 3). Detection of apoptotic activity changed at 36 hours with
few apoptotic cells being detected in cells treated with flavone A or 5-FU and several apoptotic
cells detected in cells treated in the combination. The difference in the time of apoptotic
induction correlates with the change in time of cell death for each treatment. At 24 hours, the
antineoplastic activity of flavone A can be detected, however, 5-FU take longer (48 hour) to
cause an antineoplastic effect. The combination treatment is similar to 5-FU in the time of
apoptosis and cell death induction.
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Figure 3. Combination therapy increases the induction of apoptosis in CaCo 2 cells. Caco 2
colon cancer cells were treated with 5-fluorouracil, flavone A, or a combination. TUNEL assay
was performed after 24 and 36 hours. The results shown are representative of at least three
independent assays.
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Combination treatment increases induction of apoptosis in HCT 116 cells.
To determine if a similar change in apoptotic activity occurs when flavone B is used in
combination with 5-FU, HCT 116 cells were treated with 40 µM flavone B, 80 µM 5-FU, or
combination. TUNEL assay was performed 48 or 72 hours after treatment. At 48 hours, the
majority of apoptotic cells were detected in cells treated with 5-FU with some in flavone B
treated cells (Figure 4). However, after 72 hours, the majority of apoptotic cells were detected in
the combination treatment, while the individual treatments had few apoptotic cells. This differs
from CaCo 2 and HCT 116 cells treated with 40 µM flavone A or flavone B, respectively, were
apoptosis can be detected as early as 6 hours (LeJeune et al. 2015). These data indicate that
flavone B still has some ability to induce apoptosis days after the main effect is seen. However,
as with flavone A, the apoptotic and cell death time of induction of the combination treatment is
similar to that of 5-FU.
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Figure 4. Combination therapy increases the induction of apoptosis in HCT 116 cells. HCT 116
colon cancer cells were treated with 5-fluorouracil, flavone B, or a combination. TUNEL assay
was performed after 48 and 72 hours.
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5-fluorouracil and the combination treatment increases cells cycle shift to S phase.
Both flavones and 5-FU has been shown to induce S-phase (LeJeune et al. 2015;
Robinson et al. 2006; Xiao et al. 2005). To determine if the combination treatment also induces a
similar or enhanced cell cycle shift CaCo 2 and HCT 116 cells were treated with flavone A or
flavone B, respectively, 5-FU, or combination. Annexin V-FITC and propidium iodide were used
to determine the percent of apoptotic cells and which cell cycle cells were in. 5-FU and
combination treatment caused a significant shift to S phase in the cell cycle, but did not
significantly increase apoptosis in CaCo 2 cells (Figure 5A and B). This could be a result of
timing as the flow cytometry was performed at 9 hours which may be long enough to halt the cell
cycle, but not long enough to trigger and see the effect of the apoptotic pathway. An increase in
apoptosis, as well as a shift to S-phase were seen in HCT 116 cell treated with 5-FU and
combination therapy 24 hours post dosing (Figure 5C and D). No change in cell cycle or
apoptotic activity was seen in cells dosed with either flavone individually at these time points.
However, both flavones were able to induce increases in apoptosis, S, and G2 phases in Panc 28
and HCT 116 cells 9 hours post dosing (LeJeune et al. 2015).
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Figure 5. 5-FU and combination treatment cause a cell cycle shift. (A) Caco 2 cells were treated
with flavone A, 5-fluorouracil, or combination. Propidium iodide was used to determine cell
cycle and annexin was used to determine the percent of apoptotic cells. (B) Graphical
representation of the percent of cells in cell cycle or apoptotic cells. (C) HCT 116 cells were
treated with flavone B, 5-fluorouracil, or combination. Propidium iodide was used to determine
cell cycle and annexin was used to determine the percent of apoptotic cells. (D) Graphical
representation of the percent of cells in cell cycle or apoptotic cells. * Significant (p< 0.05) from
control as determined by One-way ANOVA (Tukey).

The addition of flavone A or flavone B to 5-fluorouracil treatment causes an increase induction
of DNA damage.
The shift in time of apoptosis and cell death caused by the addition of 5-FU to the flavone
treatment raised the question of if the flavone was enhancing the DNA damage caused by 5-FU
resulting in the increase in cell death. Alkaline comet assays were performed on CaCo 2 and
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HCT 116 treated with vehicle, 40 µM flavone A or flavone B, respectively, 80 µM 5-FU, or the
combination after 24 hours. These assays determined if the combination treatment caused an
increase in both ssDNA and dsDNA damage. 5-FU and the combination treatments showed more
DNA damage than either the control or flavone treatments for both CaCo 2 and HCT 116 cells
(Figure 6A and C). Tail moments (length of tail times percent DNA in the tail) indicates that the
combination treatment cause more DNA damage per cell in comparison to the DNA damaged
caused by 5-FU alone in both cell lines (Figure 6B and D). The percent of DNA damaged cells
per population was not altered in either cell line.
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Figure 6. Combination therapy increased the induction of DNA damage. A. Comet assay was
performed CaCo 2 cells were treated with flavone A, 5-FU, or the combination for 24 hours. B.
Bar graph of the tail moments from CaCo 2 cells treated with flavone A, 5-FU, or combination.
C. Comet assay was performed on HCT 116 cells treated with flavone B, 5-FU, or combination
for 24 hours. D. Bar graph of the tail moments from HCT 116 cells treated with flavone B, 5-FU,
or combination for 24 hours. * Significant (p < 0.05) from control as determined by One-way
ANOVA (Tukey). ++ Significant (p < 0.05) from 5-FU as determined by One-way ANOVA
(Tukey).
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Flavone A and B enhances the mechanism of action of 5-fluorourail in colon cancer cells.
The complexing of the 5-FU metabolite, FdUMP, with thymidylate synthase (TS) and
CH2-THF inhibits the conversion of dUMP to dTMP causing a depletion of dTTP from the
nucleotide pool which causes dUTP to be inserted into DNA resulting in DNA damage (Figure
1) (Geng et al. 2011; Ghoshal and Jacob 1997; Peters et al. 2002). Ataxia-telangiectasia mutated
and Rad3-related (ATR) kinase response to replication stress in order to start DNA damage
repair and has increased levels in cells in response to 5-FU caused DNA damage (Woods and
Turchi 2013). ATR activates CHK1 by phosphorylation which in turn arrests the cell by
preventing the activation of CDK/cyclins (Flynn and Zou 2011). Histone H2AX is also
phosphorylated by ATR in response to DNA replication stress and recruits several DNA repair
proteins as well as chromatin remodeling complexes to the chromatin adjacent to the stressed
replication fork (Flynn and Zou 2011). When DNA damage is too extensive for repair, CHK1
initiates apoptosis through the activation of tumor-suppressor protein p53 (Wu et al. 2016).
Activated p53 induces the transcription of pro-apoptotic proteins BAX, BAK, PUMA, and
NOXA and inhibits the transcription of anti-apoptotic protein BCL-2, thus suppressing cell
survival (Chipuk et al. 2004; Goldar et al. 2015). The decrease in BCL-2 protein levels causes
the release of cytochrome c from the mitochondria allowing to bind to Apf-1 and recruit caspase
9 forming the apoptosome which in turn, cleaves and activates the effector caspase 3 causing the
execution apoptosis (Goldar et al. 2015; Pujhari et al. 2014; Zou et al. 1997). To determine if this
is the mechanism by which both flavones are able to enhance the amount of DNA damage per
cell when used in combination with 5-FU, TS, pCHK1 (Ser 345), ³ -H2AX, and BCL-2 levels
were examined.
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CaCo 2 and HCT 116 cells were treated with 40 µM flavone A or B, respectively, 80 µM
5-FU, or combination. In CaCo 2 cells, the combination treatment increased the concentration of
TS by 318% as compared to the control whereas the individual treatments of flavone A and 5-FU
caused a 40 and 77% increase, respectively, after 9 hours. In addition, the molecular weight of
the band shifted up indicating that the TS was in a complex similar to that seen with 5-FU
individual treatment (Figure 7A and B).
After 24 hours, 5-FU treatment increased the percent of pCHK1 by 17% as compared to
the control levels whereas the combination treatment increased levels by 68% in Caco 2 cells.
Flavone A by itself decreased the expression of pCHK1 by 25% (Figure 7C and D). Combination
treatment increased the level of ³ -H2AX were expression by 113% over the control and 132%
over the flavone A treatment (Figure 7E and F).
After another 5 hours (29 post dosing) changes further down the apoptotic pathway in the
form of BCL-2 levels were detected in CaCo 2 cells. Flavone A and the combination treatment
significantly decreased the BCL-2 expression to 51 and 54% of control levels, respectively. A
similar but not significant decrease in BCL-2 level was seen with 5-FU treatments (60% of the
control level (Figure 7G and H). Together, these data indicate that flavone A is able to enhance
5-FU ability to complex with TS, increase DNA damage, and activate the ATR pathway.
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Figure 7. Flavone A enhances 5-FU mechanism of action in CaCo 2 cells. (A) TS levels in CaCo
2 cells treated with vehicle, flavone A (40 µM), 5-fluorouracil (80 µM), or combination for 9
hours. (B) Graphical representation of percent of TS/actin in CaCo 2 cells. (C) pCHK1 and
CHK1 levels in CaCo 2 cells were treated with vehicle, flavone A (40 µM), 5-fluorouracil (80
µM), or combination for 24 hours. (D) Graphical representation of percent of pCHK1/actin and
CHK1/actin in CaCo 2 cells. (E) ³ -H2AX levels in CaCo 2 cells treated with vehicle, flavone A
(40 µM), 5-fluorouracil (80 µM), or combination for 24 hours. (F) Graphical representation of
percent of ³ -H2AX /actin in CaCo 2 cells. (G) BCL-2 levels in CaCo 2 cells treated with vehicle,
flavone A (40 µM), 5-fluorouracil (80 µM), or combination for 29 hours. (H) Graphical
representation of percent of BCL-2 /actin in CaCo 2 cells. Western blots are representative of
experiments performed in triplicate. * Significant (p < 0.05) from control as determined by Oneway ANOVA (Tukey). ++ Significant (p < 0.05) from 5-FU as determined by One-way ANOVA
(Tukey). *** Significant (p < 0.05) from combination treatment as determined by One-way
ANOVA (Tukey).
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Flavone B also appears to enhance the mechanism of 5-FU in a similar manner. After 24
hours, the combination treatment increased the levels of TS by 90% over the control levels. In
addition, a similar shift in molecular weight was seen, suggesting that both flavones enhance the
ability of 5-FU to complex with TS (Figure 8A and B). When used with 5-FU, flavone B was
also able to increase the activation of the ATR pathway in a more pronounce manner than
flavone A. At 24 hours, pCHK1 levels in HCT 116 cells treated with 5-FU and combination
therapies causing an increase of 277 and 400% over control levels, respectively, whereas,
flavone B alone caused a 20% increase in pCHK1 (Figure 8C and D). Individual flavone B and
5-FU treatments increased ³ -H2AX levels by 38 and 52% over the control. However, the
combination treatment increased ³ -H2AX levels by 141% over the control (Figure 8E and F).
Effects downstream in the apoptotic pathway could be detected 9 hours later (32 hours
post dosing) in BCL-2 levels. The combination treatment significantly decreased BCL-2 levels to
40% of control levels. As seen with CaCo 2 cells, individual flavone B and 5-FU treatments
decreases BCL2 levels in a similar fashion (65 and 61% of control, respectively) though these
changes were not significant (Figure 8G and H).
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Figure 8. Flavone B enhances 5-FU mechanism of action in HCT 116 cells. (A)TS levels in HCT
116 cells treated with vehicle, flavone B (40 µM), 5-fluorouracil (80 µM), or combination for 24
hours. (B) Graphical representation of percent of TS/actin in HCT 116 cells. (C) pCHK1 and
CHK1 levels in HCT 116 cells were treated with vehicle, flavone B (40 µM), 5-fluorouracil (80
µM), or combination for 24 hours. (D) Graphical representation of percent of pCHK1/actin and
CHK1/actin in HCT 116 cells. (E) ³ -H2AX levels in HCT 116 cells treated with vehicle, flavone
B (40 µM), 5-fluorouracil (80 µM), or combination for 24 hours. (F) Graphical representation of
percent of ³ -H2AX /actin in HCT 116 cells. (G) BCL-2 levels in HCT 116 cells treated with
vehicle, flavone B (40 µM), 5-fluorouracil (80 µM), or combination for 32 hours. (H) Graphical
representation of percent of BCL-2 /actin in HCT 116 cells. Western blots are representative of
experiments performed in triplicate. * Significant (p < 0.05) from control as determined by One-
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way ANOVA (Tukey). ++ Significant (p < 0.05) from 5-FU as determined by One-way ANOVA
(Tukey).
Both flavone A and flavone B increase cleavage of Caspase 3 when combined with 5fluorouracil.
Both flavones and 5-FU cause cell death via apoptosis (Fujinaka et al. 2012; Hwang et al.
2005; LeJeune et al. 2015; Thomas et al. 2012) which is triggered by cleaved effector caspases
including caspase 3 (Baig et al. 2016; Olsson and Zhivotovsky 2011). CaCo 2 cells were probed
for cleaved caspase 3 7 hours after the decrease in BCL-2 was detected (36 hours post dosing).
Cells were treated with vehicle, flavone A (40 µM), 5-FU (80 µM), or combination. A
significant increase in the cleavage of caspase 3 was seen in cells treated with the combination
versus the control (5.37 vs 0.25%) (Figure 9A and C). Similarly, HCT 116 cells treated with the
combination of flavone B (40 µM) and 5-FU (80 µM) had a significant increase in cleaved
caspase 3 to 12.88% versus 0.85% seen in the control 56 hours post dosing (Figure 9B and D).
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Figure 9. Combination treatment increases cleavage of caspase 3. (A). CaCo 2 cells treated with
vehicle, flavone A (40 µM), 5-FU (80 µM), or combination for 36 hours were probed for cleaved
caspase 3. (B) HCT 116 cells treated for 56 hours with vehicle, flavone B (40 µM), 5-FU (80
µM), or combination and probed for cleaved caspase 3. (C) Percent of CaCo 2 cell population
with cleaved caspace 3. (D) Percent of HCT 116 cell population with cleaved caspace 3. *
Significant difference (p < 0.05) as determined by One-way ANOVA (Tukey).
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5-fluorouracil and combination treatment resulted in large fluid filled tumors.
To determine whether the synergistic activity of flavone B and 5-FU also occurred in
vivo, 24 male NCruNU mice were inoculated subcutaneously with 5 x 106 HCT 116 cells in the
right flank and divided into 4 groups; control, flavone B, 5-FU, and combination treatment.
Flavone B was administer mixed in polyethylene glycol 400 (PEG 400) via intratumoral
injection at a dose of 1 mg/kg. 5-FU was mixed in saline and administered via intraperitoneal
injection at a dose of 12 mg/kg. Saline and PEG 400 were used to treat the controls. Treatments
were given and tumors measured 3 times a week. Animals were euthanized 12 days post first
treatment. At this time final tumor measurements and weight were taken after removal from the
animal (Figure 10A &B). Final tumor weight and volume were significantly different for mice
treated with the combination at 0.54 ± 0.26 g and 489 ± 354 mm3, respectively (Figure 10C &
D). Our data indicate that relative tumor volume (RTV) increased in mice treated with 5-FU or
the combination treatments 12 and 25 fold, respectively, versus the 4 and 3 fold increase that
occurred with control and flavone B treated mice, respectively, over the 12 day period (Figure
10E). Unexpectedly, tumors from mice treated with 5-FU or the combination treatment were
filled with fluid that was not found in tumors from mice in the control and flavone B treatment
groups.
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Figure 10. 5-FU and combination treatment increase the rate of tumor growth. Male NCruNU
mice with HCT 116 xenografts were treated with vehicle, flavone B (1 mg/kg), 5-FU (12 mg/kg),
or combination three times a week for 12 days via intratumoral or intraperitoneal injection. (A)
Final tumors in mice treated with control, flavone B, 5-FU, or combination, respectively. (B)
Tumors removed from mice treated with control, flavone B, 5-FU, or combination, respectively.
(C) Graphical representation of final tumor weight. (D) Graphical representation of final tumor
volume. (E) Relative tumor volume change. * Significant (p < 0.05) from control as determined
by Two-way ANOVA multiple comparison (Tukey). ++ Significant (p < 0.05) from flavone B
treatment as determined by Two-way ANOVA multiple comparison (Tukey). ** Significant (p <
0.05) from 5-FU treatment as determined by Two-way ANOVA multiple comparison (Tukey).
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Discussion
Although colon cancer has a 90% 5 year survival rate if the cancer is detected at an early
enough stage that it can be removed by surgery, the 5 year survival rate drops to 13% once the
cancer has moved to another area (American Cancer Society 2015). Unfortunately, early
detection only occurs in 40 % of cases. Common treatment for the other 60% of cases include
chemotherapy and radiation. 5-fluorouracil is the most commonly used chemotherapy for the
treatment of colon cancer and has a 10-20% response rate (Longley et al. 2003; Zhang et al.
2008). Because 5-FU cases damage to DNA, it is not cancer cell specific and results in several
side effects. One strategy to improve the effectiveness of 5-FU and potentially relieve some of
the side effects is to add a secondary drug to the therapy.
Our laboratory has previously demonstrated that flavone A and flavone B have
differential antineoplastic activity against highly tumorigenic cell lines but not against normal
cells in vitro (Thomas et al. 2012). This antineoplastic activity is caused by the induction of
apoptosis using different mechanisms (LeJeune et al. 2015). Flavone A targets more
differentiated cells causing a decrease in the active forms of pro-survival proteins ERK, S6, and
BAD triggering the intrinsic apoptotic pathway. Flavone B causes the concomitant increase in
phosphorylated ERK and c-JUN in poorly differentiated cells thus triggering an extrinsic
apoptotic pathway that is not fully understood. These pathways are activated shortly after dosing
causing the majority of effected cells to die within 24 hours.
Our results have shown in no change to cell viability in 24 hours when 5-FU is added to
the either flavone treatment (Data not shown). However, CaCo 2 cells treated with flavone A and
5-FU show a decrease in cell viability at 48 hours. HCT 116 treated with flavone B and 5-FU
also have a delay in decrease of cell viability which is seen at 72 hours. The effect of 5-FU
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individual treatment on cell viability occurred at the same time as combination treatments in both
cell lines. This suggested that the addition of 5-FU to each flavone, blocked the mechanism of
action of the flavones, possibly favoring the effect of 5-FU. Further investigation into the
mechanism via which the combination therapy caused cell death showed an increase in apoptotic
activity and shifts in cell cycle showed that these were similar to the 5-FU treatment in the time
points of occurrence, whereas, both flavones alone cause on increase in apoptosis and cell cycle
shift to the S phase at earlier time points (LeJeune et al. 2015).
5-FU can cause DNA damage by blocking the ability of cells to form dTTP resulting in
the incorporation of dUTP into DNA. Specifically, 5-FU can interact and form a complex with
thymidylate synthase and 5,10-methylene-tetrahydrofolate (Figure 1) (Geng et al. 2011; Ghoshal
and Jacob 1997; Peters et al. 2002). 5-FU induced DNA damage triggers the activation of the
ATR pathway which in turn cause an increase in the phosphorylation of histone protein H2AX
and CHK1 with the latter halting the cell cycle until the DNA can be repaired. However, if the
damage is too extensive, the p53 apoptotic pathway is triggered (Flynn and Zou 2011; Goldar et
al. 2015; Woods and Turchi 2013; Wu et al. 2016).
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Figure 11. Mechanism of combination therapy. Mechanism via which flavone A, flavone B, 5fluorouracil, and combination therapy induce apoptosis.
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The data shown here suggest an increase in the amount of TS in complex and DNA damage
when either flavone is used in combination with 5-FU as compared to 5-FU used alone. This
results in an increase in activation of the ATR pathway leading to apoptosis in cells treated with
combination therapy versus 5-FU treatment alone (Figure 11). On the contrary, the preliminary
in vivo data do not confirm these observations. Indeed, measurements of tumors on mice with
HCT 116 xenografts treated with 5-FU or combination therapy appear to have an increased rate
of tumor growth versus control and flavone B treatment (Figure 10). However, the combination
therapy appears to cause a significant change in final tumor weight and volume that was not seen
with 5-FU alone. When comparing relative tumor volume, the most striking significant
differences were seen between flavone B and combination treatment and resulted in the
combination treatment being significantly different from all other groups. This suggests that 5FU and flavone B may be working together in vivo. Further analysis of the tumor tissue looking
at changes in TS, ³ -H2AX, BCL-2, and Caspase 3 expression would be needed to determine if
the mechanism is the same in vivo as it was observed in vitro.
During the extraction of the tumors after euthanasia, several of the tumors treated with 5FU or the combination treatment were fluid-filled. This buildup of fluid in the hollow center of
the tumors may have to be taken into account when analyzing the rate of growth. To determine
whether these tumors have higher rates of necrotic cells surrounding the central cavity, histology
analysis of the tumor samples will need to be conducted. Tumor sections should be analyzed to
determine if there was an increase in cell death either by apoptosis or necrosis around the cavities
versus the exterior of the tumor. Although the fluid should have been collected to determine if
there was a difference in the type of fluid and volume between 5-FU and combination treatments,
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it may be possible to examine the width and diameter of cavities in the tumor sections to
determine if there was a size difference in the cavities.
There are many additional factors in the tumor microenvironment in an animal that are
not present in vitro. HCT 116 colon cancer cells are often used to study some of these factors and
their role in the development of resistance to chemotherapy treatments as HCT 116 cells can
easily be made resistant to 5-FU (An and Ha 2016; Jin et al. 2016; Liu et al. 2016). Two such
factors are the presence of inflammation and the effect of macrophage response. Tumorassociated macrophage (TAMs) respond to tumor cells by being activated to an M2 phenotype
which in turn promote tumor development by enhancing proliferation, metastasis, angiogenesis,
and immunosuppression (Colegio et al. 2014; Ding et al. 2015; Ghosh et al. 2015; Sousa et al.
2015; Zhou et al. 2015). It has also been shown that in response to 5-FU, TAMs secrete
putrescine which makes colon cancer cells, including HCT 116, resistant to chemotherapy in
vitro and in vivo (Zhang et al. 2016). The presence of fluid in the 5-FU and combination treated
tumors suggests the presence of inflammation and an increased recruitment of macrophages.
Examination of the tumor sections for the presence of TAMs may explain why the 5-FU and
combination treatments caused an increase in tumor size or provide insight into the mechanism
of resistance.
The increase tumor growth in mice treated with 5-FU or the combination therapy may be
the result of low, frequent dose of 5-FU. Previous studies have shown this regimen to have been
effective, however, other studies have reported the successful used higher, less frequent dosing
regimens (Akindele et al. 2015; Pereira et al. 2016; Shi et al. 2014; Wang et al. 2014b; Zhao et
al. 2010). A higher dose given once a week may cause an increase in the rate of cell death
thereby limiting the occurrence of inflammation potentially resulting in less accumulation of
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TAMs. It is also important to account for technical issues that may have affected the number of
cells inoculated into the animals that may explain the occurrence of outliers at the onset of
dosing. It is important to note that at this time there was no significant difference in tumor
volume.
Flavone B did not show a significant reduction in tumor volume in this study. However,
it did have a 48.00 ± 54.10% tumor grow inhibition compared to the control (data not shown). A
greater difference between these two groups may have been seen if The experiment was
terminated due to the size of the tumors on the 5-FU and combination groups. Furthermore, the
examination of hepatic and kidney tissue may suggest the absence of deleterious effects by
flavone B, supporting its antitumor or preventive activity in vivo
Further examination of the tissues collected from this study for toxic effects, indications
of DNA damage and cells death, as well as, the presence of macrophage are needed before
recommendations can be made involving further research with flavone A, flavone B, or the
combination treatment.
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CHAPTER 5
DISSCUSSION

The isomeric flavones, 5,7-dihydroxy-3,6,8-trimethoxy-2-phenyl-4H-chromen-4-one (5,
7–dihydroxy- 3, 6, 8 trimethoxy flavone/ flavone A) and 3,5-dihydroxy-6,7,8-trimethoxy-2phenyl-4H-chromen-4-one (3, 5–dihydroxy-6, 7, 8–trimethoxy flavone/ flavone B), from
Gnaphalium elegans and Achyrocline bogotensis have previously been shown to have
antineoplastic activity against highly tumorigenic cancers of the colon, breast, prostate, and
pancreas dependent on their differentiation status, while sparing normal cells in vitro (Thomas et
al. 2012). The hydroxyl on carbon 7 and methoxy on the carbon 3 make flavone A more
cytotoxic to better differentiated tumor cells whereas the reverse of these R groups makes
flavone B more cytotoxic to more poorly differentiated tumor cells (Chapter 1, Figure 1). These
series of studies investigated how these simple structural changes effects the pharmacokinetic,
distribution, synergistic activity, and in vivo antitumor effects of these flavones.
In order to determine the pharmacokinetics of flavone A and flavone B, methods had to
be developed to extract them from rat plasma. This was successfully done using acetonitrile as an
organic solvent with recoveries for various concentrations ranging from 84-116% (Whitted et al.
2015). Reverse-phase high performance liquid chromatography quantification methods were
developed that used different ratios of acetonitrile and water with acetic acid and triethylamine,
as well as the selection of different internal standards (celecoxib and diclofenac). In order to
obtain linear (r2 > 0.99) calibration curves, the concentrations were divided into 2 sections for
both flavones with ranges of 250-2,500 ng/mL and 2,500-100,000 ng/mL. Quantification was
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good with inter-day coefficient of variation being d 22.44 and d 16.18 for flavone A and flavone
B, respectively, and accuracies 83-111%.
These methods were used to determine the pharmacokinetics of a single 20 mg/kg IV
bolus dose of either flavone A or flavone B. It was found that flavone A has a shorter half-life
(83 vs 108 minutes) than flavone B, but both were found to have typical half-lives (< 120
minutes) as reported for flavonoids (Talbi et al. 2014; Yang et al. 2014; Zhang et al. 2014; Zhu et
al. 2015). Flavone B did have a much higher volume of distribution (11463 mL/kg) than flavone
A (986 mL/kg) which corresponded with its higher clearance (81 vs 13 mL/min/kg) and lower
area under the curve (289 vs 2492 µg*min/mL).
The difference in pharmacokinetics was partially explained when colon and pancreatic
tissues were examined for flavone A or flavone B. Filtration of the supernatant from centrifuged
tissue homogenate by a polyvinylidene fluoride (PDVF) filter (0.45 µm) allowed for the
extraction of either flavone. The HLPC methods developed for plasma resulted in good
quantification of flavone A and flavone B from colon tissue homogenate (CV 0.88 -24.03 and
1.62-33.56, respectively) using one linear (r2 >0.99) calibration curve, 250 – 100000 ng/g and
1000 – 25000 ng/g, respectively. However, the quantification method did not yield good CVs
when quantifying flavone A or flavone B from pancreatic tissue homogenate (data not shown).
The data did show that flavone B distributed to both the colon and the pancreas whereas flavone
A only distributed to the colon, which could account for some of the difference in volume of
distribution. These data indicated that both flavone A and flavone B would be viable candidates
for in vivo colon cancer assays. However, only flavone B would be a good candidate for in vivo
pancreatic cancer assays.
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With both colon and pancreatic cancer having low 5 year survival rates reported by the
American Cancer Society (American Cancer Society 2016) and having low response rates to
current chemotherapies (Longley et al. 2003; Zhang et al. 2008), new or improved treatments are
urgently needed. One way to improve the current treatment is to add a secondary therapy. Both
flavone A and flavone B were tested for decreased cell viability when used in combination with
gemcitabine or 5-fluorouracil (5-FU) against pancreatic cancer. This resulted in cell death similar
to that seen with chemotherapy treatment alone.
However, when flavone A or flavone B were combined with 5-FU against colon cancer,
there was a decrease in cell viability that was synergistic when compared to either treatment
alone. Investigation into the mechanism via which the combination treatment increased cell
death revealed that both flavone A and flavone B are capable of enhancing the amount of DNA
damage caused by 5-FU by increase the amount of thymidylate synthase in complex preventing
the conversion of dUMP to dTMP, thereby depleting dTTP from the nucleotide pool. This results
in increase caspase 3 activation and apoptosis in cells treated with both 5-FU and flavone
A/flavone B than those given an individual therapy.
Our data suggests that the synergistic effect observed in vitro, is not apparent in in vivo,
when tumor volume is considered. However, this effect may be apparent in a different manner.
As it has been shown in the previous chapter, when HCT 116 xenograft mice were treated with
5-FU or 5-FU plus flavone B, the tumor grew at an increased rate instead of the expected
diminishing in size. This resulted in the combination treatment mice having significantly larger
tumors in weight and volume. A possible explanation is that the synergistic effect could have
resulted in increased inflammation involving tumor associated macrophages which have been
previously shown to cause resistance of colon cancer cells to 5-FU and tumor proliferation as a
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result of the low dose of 5-FU used (Colegio et al. 2014; Ding et al. 2015; Ghosh et al. 2015;
Sousa et al. 2015; Zhang et al. 2016; Zhou et al. 2015). Further examination of the tumor tissue
for DNA damage, cell death, and inflammation marker such as TAMs are needed to determine if
there is indeed a synergistic effect by the combination these two agents in colon tumors
In the case of Flavone B our data suggest a slight decrease in tumor growth as compared
to the control, that may have been clearly apparent if the experiment was not terminated due to
high tumor size in 5-FU and the combination groups. The possible absence of renal or hepatic
damage by histological examination in mice treated with flavone B alone, may warrant extending
the HCT 116 xenograft experiment using just control and flavone B treated groups. Similarly,
this experiments can be conducted to if flavone A has any antitumor activity against CaCo 2
xenografts.
In conclusion, based on our pharmacokinetics and tissue distribution studies, flavone A
and flavone B are good candidates as individual treatments for colon cancer and flavone B
maybe a good candidate for the treatment of pancreatic cancer. The fact that flavone A and
flavone B target cells of varying differential status may provide an advantage for using them in
combination in vivo. The results obtained in vivo in colon cancer warrant further exploration of
using these as secondary therapies to 5-FU. Since the tumors in the 5-FU and combination
groups are fluid filled, adjustment in the dose of 5-FU in combination with flavone A or flavone
B may demonstrate a synergistic effect on colon tumors.
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